Listing 3.09 Chronic Pulmonary Hypertension in 2026: The 40 mm Hg Right Heart Cath Rule

By Anthony Albert, Benefits Research Director, Disability Exchange · Published July 11, 2026

If you've been told you have pulmonary hypertension, and every flight of stairs feels like sprinting through wet sand, you probably already know how invisible this disease is to strangers. Your resting oxygen looks okay. Your ejection fraction looks okay. Nobody sees your right heart working overtime against a lung circuit that's slowly turning to scar. And when you file for Social Security Disability, the raw feeling of breathlessness isn't what wins your case. One specific number does.

SSA has one dedicated rule for chronic pulmonary hypertension. It's Listing 3.09 in the Blue Book, and it's short. If your mean pulmonary artery pressure hits 40 mm Hg or higher on right heart catheterization, taken while you are medically stable, you meet the listing. That is the entire test. There is no walk test tucked inside 3.09, no FEV1 requirement, no oxygen saturation ladder. Just the pressure number, measured the one way that matters.

This post walks through the exact SSA text, why the number is set where it is, how the medical world's 2022 hemodynamic definition of PH differs from the SSA threshold, and what happens if you're close but not there. We'll work two real 2026 cases: one that met 3.09 outright, and one that lost on 3.09 but won on residual functional capacity at step five.

Listing 3.09 in its exact SSA wording

Straight from the 3.00 Respiratory Disorders section:

3.09 Chronic pulmonary hypertension due to any cause (see 3.00L) documented by mean pulmonary artery pressure equal to or greater than 40 mm Hg as determined by cardiac catheterization while medically stable (see 3.00E2a).

Read it slowly. Four elements. First, chronic pulmonary hypertension. Not acute, not situational, not what shows up during a chest infection. Chronic. Second, due to any cause. This is the widest door SSA cuts anywhere in Section 3. Group 1 idiopathic PAH, Group 2 left-heart-driven, Group 3 lung-disease-driven, Group 4 chronic thromboembolic, Group 5 miscellaneous. Any of them. Third, mean pulmonary artery pressure at or above 40 mm Hg. Not systolic PAP, not the echo estimate, and not the peak during exercise. Mean pressure. Fourth, from cardiac catheterization, taken while you are medically stable.

The 3.00L preamble spells out the "due to any cause" language and adds one hard constraint: SSA will not pay to have a cath done for their claim. The verbatim text is: "Chronic pulmonary hypertension is usually diagnosed by catheterization of the pulmonary artery. We will not purchase cardiac catheterization." If you don't already have that data in your medical record, you either get it through your treating pulmonologist or cardiologist, or you don't get to meet 3.09.

Why 40 mm Hg is the SSA number when the medical world moved to 20

Here's the disconnect that trips up almost every claimant who reads recent guidelines before reading the listing.

In 2022 the European Society of Cardiology and the European Respiratory Society updated the hemodynamic definition of pulmonary hypertension. The new threshold for diagnosing PH is mean pulmonary artery pressure above 20 mm Hg at rest. That was a drop from the older 25 mm Hg threshold. American guidelines have largely followed suit. The rationale is that mortality and disease progression risk start climbing well below 25.

SSA did not adopt the new hemodynamic definition. The Blue Book still says 40. That's not laziness or lag. It's a design choice. The 3.09 threshold isn't a diagnostic cutoff. It's a functional severity cutoff calibrated to disability. Once mean PAP crosses 40, most patients are clinically WHO Functional Class III or IV, right ventricular remodeling is well established, and treatment options narrow. Very few claimants at MPAP 22 mm Hg are unable to work. Many claimants at MPAP 45 mm Hg are.

The practical takeaway: your pulmonologist may have diagnosed you with PH months or years before you'd meet 3.09. That's normal. You're chronically ill under the medical definition long before you're presumptively disabled under SSA's rule.

What counts as being "medically stable" for the cath

The listing pulls in 3.00E2a for the medically stable requirement. What that section says, in plain terms, is that SSA wants values taken when you are not in an acute exacerbation, not immediately post-hospitalization, and not in the middle of an infection. If you're admitted to the ICU with acute right heart failure and someone runs a Swan-Ganz catheter, that reading isn't automatically the listing-level reading. It captures your worst hemodynamic state, not your steady state.

In real practice, this rarely blocks a claim. If your steady-state MPAP is 45 mm Hg, you'll show it on the outpatient cath your PH clinic ordered when you got referred. The people who trip over "medically stable" are ones whose only cath data comes from an ICU admission during a decompensation, and whose outpatient echo estimate is much lower.

Right heart cath vs echo estimate: why the choice of test decides your case

Every echo report gives an estimated pulmonary artery systolic pressure using tricuspid regurgitation velocity plus estimated right atrial pressure. That number floats around your record like a fact. It isn't the listing measure. Listing 3.09 uses mean pulmonary artery pressure from cath, not systolic PAP from echo.

Two clinical points matter here. First, echo systolic PAP tends to correlate loosely with cath MPAP. A conversion of roughly MPAP = 0.61 x sPAP + 2 is used in some studies, but the confidence intervals are wide. An echo sPAP of 65 might correspond to a cath MPAP of 42, or 35, or 50, depending on the patient. Second, echo consistently misses PH driven by left heart disease and is unreliable in patients with lung disease that distorts the tricuspid regurgitation jet.

If your only PH documentation is an echo estimate, and you're clinically limited, request that your pulmonologist send you for a right heart cath through a PH center. That single test can be the difference between a denial at step three and a listing meet at step three.

What causes chronic pulmonary hypertension: the five WHO groups and how they meet 3.09

Group 1: Pulmonary Arterial Hypertension

Group 1 is what most people picture when they hear "pulmonary hypertension." Idiopathic PAH, heritable PAH (BMPR2 mutations), connective tissue disease PAH (scleroderma is the biggest driver), HIV-associated PAH, congenital heart disease PAH, and portopulmonary hypertension in cirrhosis. Drug-induced PAH from historic diet drugs still shows up too. In Group 1, cath is standard of care and MPAP data is almost always in the record.

Group 2: PH due to left heart disease

This is the largest group by patient count. Heart failure with reduced or preserved ejection fraction, valvular disease, congenital left heart obstruction. In Group 2 the pathophysiology is postcapillary. The wedge pressure is elevated. Cath is common but MPAP frequently sits between 30 and 40, which puts many Group 2 patients just below the listing threshold. Group 2 claimants often win on cardiac listings 4.02 (chronic heart failure) plus RFC, rather than 3.09.

Group 3: PH due to lung diseases and/or hypoxia

COPD, interstitial lung disease including IPF, combined pulmonary fibrosis and emphysema, sleep-disordered breathing, high altitude exposure. Group 3 patients frequently meet the underlying lung listings 3.02 or the newer chronic respiratory disorders criteria before their PH numbers cross 40. The overlap is real. If your COPD FEV1 is at Table I level and your MPAP is 38, you meet 3.02 easily and 3.09 is redundant.

Group 4: Chronic Thromboembolic PH (CTEPH)

CTEPH follows unresolved pulmonary emboli. Roughly 3 to 4 percent of acute PE survivors develop it. Cath is required for diagnosis and treatment planning, and MPAP data is usually well documented. CTEPH is the one form of PH that is potentially curable through pulmonary endarterectomy at specialized centers, or treatable with balloon pulmonary angioplasty and riociguat in inoperable cases. If you're pre-surgery with an MPAP of 55, you likely meet 3.09. If you're post-endarterectomy with MPAP now 28, you don't, but SSA will look at your durable functional loss.

Group 5: Multifactorial mechanisms

Sarcoidosis, chronic hemolytic anemia including sickle cell disease, chronic kidney disease on dialysis, thyroid disease, and glycogen storage diseases. Group 5 is heterogeneous. Cath data may or may not be routine depending on the driving condition.

2026 PH treatments and why they don't disqualify you from 3.09

PH pharmacotherapy has expanded substantially. As of 2026, standard PAH regimens include:

• PDE-5 inhibitors: sildenafil (Revatio), tadalafil (Adcirca)
• Endothelin receptor antagonists: bosentan (Tracleer), ambrisentan (Letairis), macitentan (Opsumit)
• Prostacyclin analogs: epoprostenol (Flolan, Veletri) IV, treprostinil (Remodulin IV/SC, Tyvaso inhaled/oral), iloprost (Ventavis inhaled), selexipag (Uptravi) oral prostacyclin receptor agonist
• Soluble guanylate cyclase stimulator: riociguat (Adempas), the mainstay in inoperable CTEPH
• Activin signaling inhibitor: sotatercept (Winrevair), FDA approved March 2024 for PAH, adding a new mechanism after decades of the same three drug classes

Sotatercept in the STELLAR trial improved 6-minute walk distance by roughly 40 meters at 24 weeks, reduced clinical worsening, and lowered PVR. That's meaningful clinically. It does not knock you out of Listing 3.09. What matters for the listing is your medically stable MPAP. If you're on triple therapy including sotatercept and your MPAP is still 42, you meet. If your medications get your MPAP down to 30, you no longer meet, but you may still be limited enough for an RFC win.

Same logic applies for CTEPH. Post-endarterectomy hemodynamics that normalize likely take you out of 3.09. Persistent post-endarterectomy PH with MPAP still above 40 keeps you in.

Working case A: Vivian, 52, Charlotte NC, idiopathic PAH

What made this case clean: the treating PH center clearly labeled the outpatient cath as reflecting stable state, and the MPAP at that reading was comfortably above 40. Vivian wasn't a borderline case. She met the listing on the number that matters.

Working case B: Marcus, 60, Detroit MI, HFpEF-driven Group 2 PH

Marcus's case shows the value of not treating 3.09 as your only path. When cath data doesn't hit 40, you build the case on functional loss across systems and force the ALJ to grapple with the whole clinical picture. Group 2 patients particularly benefit from combining cardiac and pulmonary listings analysis with a well-supported RFC.

What to have in your file before you file

If you're preparing an SSDI or SSI claim on chronic pulmonary hypertension, this is the documentation checklist that will actually change the outcome:

• Right heart catheterization report with explicit MPAP value. Not just an echo. If you haven't had cath, ask your pulmonologist why not.
• A treating physician's statement that the cath was performed while medically stable, or if unstable, an outpatient study on background therapy.
• WHO Functional Class assessment in the record.
• 6-minute walk test with distance and oxygen saturation nadir. Not required by 3.09 but critical for RFC development.
• Full echo with tricuspid regurgitation velocity and estimated PASP as supporting data.
• NT-proBNP or BNP trend across at least three visits.
• Complete medication list, including any titration history on PAH-specific therapy.
• REVEAL 2.0 risk score if calculated by your PH center. Not required, but persuasive at hearing.

What to do if your MPAP is 35 to 39 mm Hg

You're in the frustrating middle zone. Real disease, real limitations, wrong side of the number. Three things to focus on:

First, ask whether your cath was done truly at medically stable state on optimized therapy. If it was done on partial therapy and you've since added sotatercept, a second cath in six to twelve months may show progression above 40 if you're truly progressive. It may also show improvement, which is a good clinical outcome even if it hurts the listing case.

Second, build the RFC file. Document oxygen desaturation with exertion, syncope or presyncope history, arrhythmias, right ventricular dysfunction on echo, chronic anticoagulation risks. Objective functional testing beats symptom self-report every time.

Third, look at cross-body-system listings. If your PH is driven by ILD, look hard at whether you meet Blue Book 3.02 for chronic respiratory disorders on FVC, DLCO, or A-a gradient. If PH is driven by connective tissue disease, systemic sclerosis or lupus may open Listing 14.04 or 14.02.

State pages for local PH clinics and DDS quirks

State-level Determination Services offices interpret respiratory listings consistently in theory but have local reviewer patterns worth knowing. If you're filing in a state that already has a Pulmonary Hypertension Association-accredited Center of Care, your cath data usually reads clean. Start here:

• North Carolina SSDI resources
• Michigan SSDI resources
• Florida SSDI resources
• Texas SSDI resources
• California SSDI resources

Related listings and articles

• Listing 3.02 Chronic Respiratory Disorders: FEV1, FVC, DLCO thresholds for 2026
• Listing 3.03 Asthma: The three hospitalizations rule
• Listing 3.04 Cystic Fibrosis
• Listing 4.02 Chronic Heart Failure: EF, NYHA, 6-minute walk

Frequently asked questions